Journal of International Oncology››2024,Vol. 51››Issue (5): 280-285.doi:10.3760/cma.j.cn371439-20231017-00047
• Original Articles •Previous ArticlesNext Articles
Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao()
Received:
2023-10-17Revised:
2024-01-29Online:
2024-05-08Published:
2024-06-26Contact:
Chen Dachao, Email:19905969119@163.comWang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
"
临床病理特征 | 癌结节组 (n=50) |
无癌结节组 (n=146) |
t/χ2值 | P值 | 临床病理特征 | 癌结节组 (n=50) |
无癌结节组 (n=146) |
t/χ2值 | P值 |
---|---|---|---|---|---|---|---|---|---|
年龄(岁) | 59.60±5.49 | 60.04±4.80 | -0.55 | 0.585 | 肿瘤最大长径(cm) | ||||
性别 | ≥5 | 23 | 30 | 12.23 | <0.001 | ||||
男 | 26 | 89 | 1.23 | 0.267 | <5 | 27 | 116 | ||
女 | 24 | 57 | 肿瘤部位 | ||||||
糖尿病 | 左半结肠 | 19 | 58 | 0.05 | 0.829 | ||||
有 | 14 | 29 | 1.44 | 0.230 | 右半结肠 | 31 | 88 | ||
无 | 36 | 117 | 病理类型 | ||||||
高血压 | 腺癌 | 31 | 104 | 3.44 | 0.179 | ||||
有 | 16 | 29 | 3.10 | 0.078 | 黏液腺癌 | 13 | 35 | ||
无 | 34 | 117 | 其他 | 6 | 7 | ||||
肠梗阻 | 肿瘤分化 | ||||||||
有 | 8 | 20 | 0.16 | 0.688 | 低分化 | 10 | 21 | 0.88 | 0.348 |
无 | 42 | 126 | 中高分化 | 40 | 125 | ||||
CA19-9(U/ml) | T分期 | ||||||||
>40 | 16 | 21 | 7.55 | 0.006 | T3-4 | 23 | 26 | 15.79 | <0.001 |
≤40 | 34 | 125 | T1-2 | 27 | 120 | ||||
CEA(ng/ml) | 脉管癌栓 | ||||||||
>5 | 12 | 20 | 2.89 | 0.089 | 有 | 19 | 21 | 12.79 | <0.001 |
≤5 | 38 | 126 | 无 | 31 | 125 | ||||
组织类型 | 淋巴结转移 | ||||||||
隆起型 | 26 | 54 | 5.37 | 0.068 | 有 | 26 | 32 | 16.18 | <0.001 |
溃疡型 | 19 | 83 | 无 | 24 | 114 | ||||
浸润型 | 5 | 9 |
"
项目 | 肝转移 (n=46) |
无肝转移 (n=150) |
t/χ2值 | P值 | 项目 | 肝转移 (n=46) |
无肝转移 (n=150) |
t/χ2值 | P值 |
---|---|---|---|---|---|---|---|---|---|
年龄(岁) | 60.50±5.01 | 59.76±4.97 | 0.88 | 0.380 | 肿瘤部位 | ||||
性别 | 左半结肠 | 19 | 58 | 0.10 | 0.749 | ||||
男 | 28 | 87 | 0.12 | 0.730 | 右半结肠 | 27 | 92 | ||
女 | 18 | 63 | 病理类型 | ||||||
糖尿病 | 腺癌 | 30 | 105 | ||||||
有 | 10 | 33 | 0.01 | 0.970 | 黏液腺癌 | 10 | 38 | 4.03 | 0.134 |
无 | 36 | 117 | 其他 | 6 | 7 | ||||
高血压 | 肿瘤分化 | ||||||||
有 | 10 | 35 | 0.05 | 0.822 | 低分化 | 10 | 21 | 1.58 | 0.208 |
无 | 36 | 115 | 中高分化 | 36 | 129 | ||||
肠梗阻 | T分期 | ||||||||
有 | 9 | 19 | 1.37 | 0.242 | T3-4 | 17 | 32 | 4.58 | 0.032 |
无 | 37 | 131 | T1-2 | 29 | 118 | ||||
CA19-9(U/ml) | 脉管癌栓 | ||||||||
>40 | 15 | 22 | 7.40 | 0.007 | 有 | 18 | 22 | 12.97 | <0.001 |
≤40 | 31 | 128 | 无 | 28 | 128 | ||||
CEA(ng/ml) | 淋巴结转移 | ||||||||
>5 | 8 | 24 | 0.05 | 0.823 | 有 | 19 | 39 | 3.96 | 0.047 |
≤5 | 38 | 126 | 无 | 27 | 111 | ||||
组织类型 | 癌结节 | ||||||||
隆起型 | 21 | 59 | 有 | 33 | 17 | 67.60 | <0.001 | ||
溃疡型 | 20 | 82 | 2.36 | 0.307 | 无 | 13 | 133 | ||
浸润型 | 5 | 9 | 癌结节直径(cm) | 1.15±0.17 | 0.77±0.20 | 4.28 | <0.001 | ||
手术方式 | 癌结节数量(枚) | ||||||||
腹腔镜 | 23 | 71 | 0.10 | 0.751 | 0 | 13 | 133 | 68.77 | <0.001 |
开腹 | 23 | 79 | 1 | 22 | 9 | ||||
肿瘤最大长径(cm) | 2 | 5 | 4 | ||||||
≥5 | 20 | 33 | 8.23 | 0.004 | 3 | 6 | 4 | ||
<5 | 26 | 117 |
"
因素 | β值 | SE值 | Waldχ2值 | OR值 | 95%CI | P值 |
---|---|---|---|---|---|---|
CA19-9 | 1.08 | 0.68 | 2.52 | 2.94 | 0.87~5.97 | 0.172 |
肿瘤最大长径 | 1.04 | 0.87 | 1.42 | 2.83 | 0.48~3.06 | 0.835 |
T3-4期 | 1.53 | 0.70 | 4.78 | 4.62 | 1.51~7.35 | 0.003 |
脉管癌栓 | 1.69 | 0.94 | 3.23 | 5.42 | 1.75~12.85 | <0.001 |
淋巴结转移 | 1.20 | 0.74 | 2.63 | 3.20 | 0.76~7.74 | 0.422 |
癌结节 | 2.92 | 1.66 | 3.09 | 18.54 | 7.45~39.73 | <0.001 |
癌结节直径 | 2.58 | 1.57 | 2.70 | 13.20 | 4.74~29.64 | <0.001 |
癌结节数量 | ||||||
1枚 | 2.21 | 1.64 | 1.82 | 9.11 | 2.24~27.34 | <0.001 |
2枚 | 1.85 | 0.72 | 6.60 | 6.36 | 1.38~9.08 | <0.001 |
3枚 | 1.61 | 0.88 | 3.35 | 5.00 | 1.98~8.84 | <0.001 |
[1] | Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020[J].CA Cancer J Clin,2020,70(3): 145-164. DOI:10.3322/caac.21601. |
[2] | 中华人民共和国国家卫生健康委员会. 中国结直肠癌诊疗规范(2020年版)[J].中华外科杂志,2020,58(8): 561-585. DOI:10.3760/cma.j.cn112139-20200518-00390. |
[3] | Yoshino K, Osumi H, Ito H, et al. Clinical usefulness of postoperative serum carcinoembryonic antigen in patients with colorectal cancer with liver metastases[J].Ann Surg Oncol,2022,29(13): 8385-8393. DOI:10.1245/s10434-022-12301-w. |
[4] | Chen GA, Zhu WQ, Liu Y, et al. The clonal heterogeneity of colon cancer with liver metastases[J].J Gastroenterol,2023,58(7): 642-655. DOI:10.1007/s00535-023-01989-6. pmid:37042990 |
[5] | Zhao JF, Zhu JF, Huang C, et al. Impact of primary tumor resection on the survival of patients with unresectable colon cancer liver metastasis at different colonic subsites: a propensity score matching analysis[J].Acta Chir Belg,2023,123(2): 132-147. DOI:10. 1080/00015458.2021.1956799. |
[6] | 崔艳成, 周宇石, 申占龙, 等. 癌结节对根治性手术后Ⅲ期结肠癌患者预后的影响[J].中华普通外科杂志,2022,37(4): 260-264. DOI:10.3760/cma.j.cn113855-20220303-00122. |
[7] | 安琦, 史金鑫, 崔健, 等. 高龄左、右半结肠癌患者切除术预后情况及其相关因素分析[J].中华医学杂志,2023,103(22): 1666-1672. DOI:10.3760/cma.j.cn112137-20221008-02102. |
[8] | Boudjema K, Locher C, Sabbagh C, et al. Simultaneous versus delayed resection for initially resectable synchronous colorectal cancer liver metastases: a prospective, open-label, randomized, controlled trial[J].Ann Surg,2021,273(1): 49-56. DOI:10.1097/SLA.0000000 000003848. |
[9] | 陈佳琦, 翁姗姗, 胡涵光, 等. 结直肠癌肝转移的转化治疗[J].中华肝胆外科杂志,2020,26(7): 493-495. DOI:10.3760/cma.j.cn113884-20200421-00217. |
[10] | Padmanabhan C, Nussbaum DP, D'Angelica M. Surgical management of colorectal cancer liver metastases[J].Surg Oncol Clin N Am,2021,30(1): 1-25. DOI:10.1016/j.soc.2020.09.002. pmid:33220799 |
[11] | Tan KR, Leong SM, Kee ZZ, et al. Longitudinal monitoring reveals dynamic changes in circulating tumor cells (CTCs) and CTC-associated miRNAs in response to chemotherapy in metastatic colorectal cancer patients[J].Cancer Lett,2018,423: 1-8. DOI:10.1016/j.canlet.2018.02.039. pmid:29518480 |
[12] | Iwai T, Yamada T, Takahashi G, et al. Circulating cell-free long DNA fragments predict post-hepatectomy recurrence of colorectal liver metastases[J].Eur J Surg Oncol,2020,46(1): 108-114. DOI:10.1016/j.ejso.2019.08.010. pmid:31431321 |
[13] | Cohen R, Shi Q, Meyers J, et al. Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage Ⅲ colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase Ⅲ study (Alliance)☆[J].Ann Oncol,2021,32(10): 1267-1275. DOI:10.1016/j.annonc.2021. 07.009. pmid:34293461 |
[14] | Schrempf M, Anthuber M. Importance of tumor deposits in patients with stage Ⅲ colon cancer[J].Chirurg,2020,91(9): 781. DOI:10.1007/s00104-020-01254-z. pmid:32728784 |
[15] | Delattre JF, Cohen R, Henriques J, et al. Prognostic value of tumor deposits for disease-free survival in patients with stage Ⅲ colon cancer: a post hoc analysis of the IDEA France phase Ⅲ trial (PRODIGE-GERCOR)[J].J Clin Oncol,2020,38(15): 1702-1710. DOI:10.1200/JCO.19.01960. |
[16] | 张娟, 樊维宁, 刘新兰. 癌结节与Ⅲ期结直肠癌患者预后的相关性分析[J].西安交通大学学报(医学版),2020,41(1): 97-101, 119. DOI:10.7652/jdyxb202001018. |
[17] | 黎华丽, 程煌荣, 杨超, 等. 结直肠癌系膜癌结节相关的病理因素及预后分析[J].腹部外科,2021,34(1): 44-48, 53. DOI:10.3969/j.issn.1003-5591.2021.01.011. |
[18] | 梁佳英, 王畅, 王轶卓. 癌结节与结直肠癌临床分期及预后关系的研究进展[J].癌症,2022,10(41): 458-474. |
[19] | Mizuuchi Y, Tanabe Y, Sada MSF, et al. Relationship between prognostic impact of N3lymph node metastasis at the root of the feeding artery and location of colon cancer[J].Langenbecks Arch Surg,2023,408(1): 31. DOI:10.1007/s00423-023-02778-8. |
[20] | Bananzadeh A, Daneshvar Jahromi A, Emami Meybodi A, et al. Prognostic factors of recurrence and survival in operated patients with colorectal cancer[J].Middle East J Dig Dis,2022,14(1): 44-50. DOI:10.34172/mejdd.2022.254. |
[21] | Dou X, Xi J, Zheng G, et al. A nomogram was developed using clinicopathological features to predict postoperative liver metastasis in patients with colorectal cancer[J].J Cancer Res Clin Oncol,2023,149(15): 14045-14056. DOI:10.1007/s00432-023-05168-1. pmid:37548773 |
[22] | 刘庆睿, 姜宪. 结肠癌肝转移患者临床特征及预后危险因素分析: 基于SEER数据库[J].消化肿瘤杂志(电子版),2022,14(1): 65-70. DOI:10. 3969/j.issn.1674-7402.2022.01.011. |
[23] | Fleming CA, Jordan P, O'Leary DP, et al. Perioperative cell-free DNA trends predict recurrence of non-metastatic colorectal cancer significantly earlier than CEA trends over the first 2 years post-operatively in stage Ⅱ and stage Ⅲ colon cancer[J].Int J Colorectal Dis,2022,37(5): 1119-1126. DOI:10.1007/s00384-022-04133-7. |
[24] | Luo DK, Yang YF, Shan ZZ, et al. Clinicopathological features of stage Ⅰ-Ⅲ colorectal cancer recurrence over 5 years after radical surgery without receiving neoadjuvant therapy: evidence from a large sample study[J].Front Surg,2021,8: 666400. DOI:10. 3389/fsurg.2021.666400. |
[25] | 秦琼, 杨林, 周爱萍, 等. 癌结节对Ⅲ期结肠癌患者预后的影响及将癌结节数目纳入淋巴结计数整体评估TNM分期的探索性研究[J].中华胃肠外科杂志,2019,22(12): 1152-1158. DOI:10.3760/cma.j.issn.1671-0274.2019.12.010. |
[1] | Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375. |
[2] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[3] | Wang Kun, Zhou Zhongxin, Zang Qiwei.Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection[J]. Journal of International Oncology, 2024, 51(4): 198-203. |
[4] | Zhang Lili, Tan Ru, Fang Xueli, Yang Yu, Sang Zheng, Li Baosheng.Imaging diagnosis, pathological upgrade, and imaging technology progress of ductal carcinomain situof the breast[J]. Journal of International Oncology, 2024, 51(3): 166-169. |
[5] | Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118. |
[6] | Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong.Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474. |
[7] | Chen Zhuo, Tao Jun, Chen Lin, Ke Jing.Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer[J]. Journal of International Oncology, 2023, 50(5): 268-273. |
[8] | Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun.Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases[J]. Journal of International Oncology, 2023, 50(3): 138-143. |
[9] | Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun.Construction of postoperative prognosis model for patients with colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 157-163. |
[10] | Xu Liangfu, Li Yuanfei.Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 186-190. |
[11] | Liu Yujie, Zhao Zhiqiang, Wang Zicheng.Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer[J]. Journal of International Oncology, 2023, 50(12): 717-722. |
[12] | Gong Heyi, Yi Yan, Zhang Jian, Li Baosheng.Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy[J]. Journal of International Oncology, 2023, 50(12): 745-750. |
[13] | Chen Yu, Xu Hua, Liu Hai, Chen Shixin.Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging[J]. Journal of International Oncology, 2023, 50(11): 655-660. |
[14] | Tao Hong, Yin Hong, Luo Hong, Tao Jiayu.Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer[J]. Journal of International Oncology, 2023, 50(11): 683-687. |
[15] | Wang Xi, Wu Chuanqing.Research progress in reversing multidrug resistance in colorectal cancer[J]. Journal of International Oncology, 2023, 50(1): 42-46. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||